Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

Inclusion Criteria: * Male or female subjects ≥18 years of age able to give written informed consent to the study * Hemodialysis dependent chronic kidney disease stage 5D patients * Taking sevelamer carbonate tablets or sevelamer hydrochloride as phosphate binder monotherapy * Taking 3 or more sevelamer carbonate or sevelamer hydrochloride tablets per day Exclusion Criteria: * Estimated life expectancy of less than 6 months and for cancer patients, an Eastern Cooperative Oncology Group (ECOG) Performance Status \>1 * Active malignancy within the past 5 years. Basal or squamous cell skin cancer is not exclusionary. History of malignancy is not an exclusion * Known hypersensitivity reaction to calcium-based phosphate binders * Anticipated renal transplantation during the study * Pregnant or sexually active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception.